Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients

Transplantation

Volumn 94, Issue 2, 2012, Pages 165-171

  Alachkar, Nada ^a   Lonze, Bonnie E ^a   Zachary, Andrea A ^a   Holechek, Mary J ^a   Schillinger, Karl ^a   Cameron, Andrew M ^a   Desai, Niraj M ^a   Dagher, Nabil N ^a   Segev, Dorry L ^a   Montgomery, Robert A ^a   Singer, Andrew L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Desensitization; Intravenous immunoglobulin; Kidney transplantation

Indexed keywords

HLA ANTIBODY; IMMUNOGLOBULIN; PANEL REACTIVE ANTIBODY;

ADULT; ALLOGRAFT; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; BLOOD ANALYSIS; BLOOD GROUP TYPING; CADAVER DONOR; CALCULATE PANEL REACTIVE ANTIBODY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DESENSITIZATION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; IMMUNOCYTOTOXICITY; IMMUNOLOGICAL PARAMETERS; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIZATION; TREATMENT RESPONSE;

ADULT; COHORT STUDIES; FEMALE; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84864280878     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318253f7b6     Document Type: Article

References (27)

1. Network OPT. Scientific registry of transplant recipients: OPTN: data. 2011. Available at: http://optn.transplant.hrsa.gov/. Accessed June 1, 2011.
2. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359(3): 242.
3. Montgomery RA, Zachary AA, Ratner LE, et al. Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation. JAMA 2005; 294(13): 1655.
4. Segev DL, Gentry SE, Warren DS, et al. Kidney paired donation and optimizing the use of live donor organs. JAMA 2005; 293(15): 1883.
5. Montgomery RA, Gentry SE, Marks WH, et al. Domino paired kidney donation: a strategy to make best use of live non-directed donation. Lancet 2006; 368(9533): 419.
6. Rees MA, Kopke JE, Pelletier RP, et al. A nonsimultaneous, extended, altruistic-donor chain. N Engl J Med 2009; 360(11): 1096.
7. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-matchYpositive recipients. Transplantation 2000; 70(6): 887.
8. Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3(8): 1017.
9. Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 2009; 9(3): 536.
10. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004; 8(6): 535.
11. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLAincompatible kidney recipients and survival. N Engl J Med 2011; 365(4): 318.
12. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2(8): 758.
13. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15(12): 3256.
14. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. AmJ Transplant 2006; 6(2): 346.
15. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89(9): 1095.
16. Jordan SC, Toyoda M, Vo AA. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 2009; 88(1): 1.
17. Jordan SC, Toyoda M, Vo AA. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol 2011; 7(3): 341.
18. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345(10): 747.
19. Sapir T, Shoenfeld Y. Facing the enigma of immunomodulatory effects of intravenous immunoglobulin. Clin Rev Allergy Immunol 2005; 29(3): 185.
20. Watanabe J, Scornik JC. IVIG and HLA antibodies. Evidence for inhibition of complement activation but not for anti-idiotypic activity. Am J Transplant 2005; 5(11): 2786.
21. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 513.
22. Glotz D, Antoine C, Julia P, et al. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transpl Int 2004; 17(1): 1.
23. Kozlowski T, Andreoni K. Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time? Ann Transplant 2011; 16(2): 19.
24. Zachary AA, Sholander JT, Houp JA, et al. Using real data for a virtual crossmatch. Hum Immunol 2009; 70(8): 574.
25. Zachary AA, Lucas DP, Detrick B, et al. Naturally occurring interference in Luminex assays for HLA-specific antibodies: characteristics and resolution. Hum Immunol 2009; 70(7): 496.
26. Cecka JM. Calculated PRA (CPRA): the new measure of sensitization for transplant candidates. Am J Transplant 2010; 10(1): 26.
27. Zachary AA, Montgomery RA, Leffell MS. Defining unacceptable HLA antigens. Curr Opin Organ Transplant 2008; 13(4): 405.